Idorsia is a high-potential biopharmaceutical company, with an experienced team of over 1,200 highly qualified professionals, a full R&D pipeline, state-of-the-art facilities, and a strong balance sheet – the ideal constellation for bringing successful medicines to the market.
We began our operations after demerging from Actelion following its acquisition by Johnson & Johnson in 2017. At that time, approximately 650 talented and engaged employees were transferred to Idorsia, together with the discovery pipeline and early-stage clinical assets.
Idorsia is specialized in the discovery and development of small molecules, with the aim of transforming the horizon of therapeutic options. We have a broad, diversified and balanced development pipeline, covering multiple therapeutic areas. Our clinical pipeline comprises 11 assets, 6 of which are in late-stage development, and we expect to see two product launches in two of the largest pharmaceutical markets in the second quarter of 2022. With this in mind, we have built a commercial organization to bring our products to patients.
Idorsia is a start-up like no other!